|
18 Oct 2022 |
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
|
|
18 Oct 2022 |
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
|
|
17 Oct 2022 |
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
|
|
12 Oct 2022 |
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs
|
|
12 Oct 2022 |
Ascidian Therapeutics Launches to Rewrite RNA
|
|
12 Oct 2022 |
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK
|
|
12 Oct 2022 |
Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery
|
|
10 Oct 2022 |
RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology; Michael Lee-Chin appointed to the board of the company
|
|
06 Oct 2022 |
Nested Therapeutics Launches With $125 Million Financing
|
|
06 Oct 2022 |
Amphista Therapeutics partners with Domainex to advance portfolio of drug discovery projects targeting protein degradation
|
|
05 Oct 2022 |
Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform
|
|
05 Oct 2022 |
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
|
|
05 Oct 2022 |
SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics
|
|
05 Oct 2022 |
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
|
|
04 Oct 2022 |
Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming
|
|
03 Oct 2022 |
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
|
|
03 Oct 2022 |
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
|
|
30 Sep 2022 |
Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program
|
|
29 Sep 2022 |
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
|
|
28 Sep 2022 |
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
|
|
28 Sep 2022 |
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology
|
|
28 Sep 2022 |
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
|
|
22 Sep 2022 |
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
|
|
21 Sep 2022 |
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
|
|
21 Sep 2022 |
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
|
